Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports

Eli Lilly is moving to acquire the psychedelic biotech firm AtaiBeckley in a deal valued at up to $3.8 billion. According to reports from Reuters, Bloomberg, and Yahoo Finance, the acquisition is designed to advance therapies for mental health conditions, specifically focusing on treatment-resistant depression. The deal involves the developer of 5-MeO-DMT, as noted by Psychedelic Alpha. While some reports from CNBC and Yahoo Finance initially cited a $2.8 billion figure, other coverage, including that from Bloomberg and Reuters, indicates the total value could reach $3.8 billion. Multiple financial news outlets have highlighted the immediate market reaction to this news. Seeking Alpha reported that AtaiBeckley shares soared 66% amid buyout talks, while Barron's noted a 50% increase in the stock price.

Yahoo Finance further detailed that some venture capitalists anticipate a takeover premium of up to 105% from Eli Lilly. The Financial Times emphasized that AtaiBeckley is a psychedelic biotech firm backed by Peter Thiel. The transaction marks a significant strategic pivot for Eli Lilly as it enters the psychedelic drug race. Context provided by PR Newswire indicates that the primary goal of the acquisition is to develop and advance treatments for individuals who do not respond to traditional depression therapies. The broader industry trend involves experimental psychedelic treatments gaining traction, according to CNBC. AtaiBeckley's position as a developer of 5-MeO-DMT places it at the center of this medical shift, with the world's largest pharmaceutical company, Eli Lilly, now betting on these specific therapies to address unmet needs in mental health care.

Future developments to monitor include the finalization of the acquisition terms and the regulatory path for the 5-MeO-DMT therapies. Market watchers will likely track whether AtaiBeckley stock returns to its four-year highs, a possibility raised by Yahoo Finance. Coverage does not yet specify the exact closing date of the deal or the full list of mental health conditions beyond treatment-resistant depression that the acquired technology will target. Observers will be looking for official confirmation on the final purchase price, given the variance between the $2.8 billion and $3.8 billion figures reported across different outlets.